GlaxoSmithKline Pharmaceuticals Limited Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹2506.3Market Cap
₹ 41,579 Cr.Stock P/E
43.2ROE
45.6 %RSI
59.94Trend
BullishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Glaxosmithkline Pharmaceuticals Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest Glaxosmithkline Pharmaceuticals Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the Glaxosmithkline Pharmaceuticals Ltd share price chart currently indicates a Bullish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 2506.3 |
| RSI (14) | 59.94 |
| 50 DMA | 2329.26 |
| 200 DMA | 2463.21 |
| Trend | Bullish |
| A/D Rating | C |
| RS Rating | 31 |
| EPS Rating | 59 |
| TI65 | 1.04 |
| TI65 Trend | Neutral |
Pivot Points Analysis
Daily pivot points for GlaxoSmithKline Pharmaceuticals Limited calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹2569.26 |
| R2 | ₹2540.63 |
| R1 | ₹2523.46 |
| PP | ₹2494.83 |
| S1 | ₹2477.66 |
| S2 | ₹2449.03 |
| S3 | ₹2431.86 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 41,579 Cr. |
| Current Price | ₹ 2,455 |
| High / Low | ₹ 3,220 / 2,088 |
| Stock P/E | 43.2 |
| Book Value | ₹ 134 |
| Dividend Yield | 2.32 % |
| ROCE | 61.4 % |
| ROE | 45.6 % |
| Face Value | ₹ 10.0 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 787 | 133 | 22% |
| Jun 2023 | 762 | 132 | 19% |
| Sep 2023 | 957 | 218 | 30% |
| Dec 2023 | 805 | 46 | 27% |
| Mar 2024 | 930 | 194 | 28% |
| Jun 2024 | 815 | 182 | 28% |
| Sep 2024 | 1,011 | 252 | 32% |
| Dec 2024 | 949 | 230 | 31% |
| Mar 2025 | 974 | 263 | 34% |
| Jun 2025 | 805 | 205 | 31% |
| Sep 2025 | 980 | 257 | 34% |
| Dec 2025 | 1,041 | 296 | 36% |
| Mar 2026 | 995 | 278 | 35% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 75.00% |
| FIIs | 1.82% |
| DIIs | 10.26% |
| Government | 0.01% |
| Public | 12.92% |
| No. of Shareholders | 1,00,371 |
Pros and Cons
Pros
- Healthy return on equity of 45.6% indicating strong capital allocation efficiency.
- Strong technical momentum with price holding comfortably above the 50 DMA (2329.26).
Cons
Related NSE Stocks
Thermax Limited
View Share Price Analysis →Engineers India Limited
View Share Price Analysis →Tata Motors Limited
View Share Price Analysis →Jupiter Wagons Limited
View Share Price Analysis →Garden Reach Shipbuilders & Engineers Limited
View Share Price Analysis →Pfizer Limited
View Share Price Analysis →IRB Infrastructure Developers Limited
View Share Price Analysis →Home First Finance Company India Limited
View Share Price Analysis →Tata Communications Limited
View Share Price Analysis →Vishal Mega Mart Limited
View Share Price Analysis →Indian Bank
View Share Price Analysis →Firstsource Solutions Limited
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for Glaxosmithkline Pharmaceuticals Ltd share?
Based on the latest closing data, the technical momentum for Glaxosmithkline Pharmaceuticals Ltd is currently evaluated as Bullish. The stock is exhibiting an RSI (14) of 59.94, indicating it is trading in a neutral balanced zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (2329.26) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for Glaxosmithkline Pharmaceuticals Ltd?
According to Classic Pivot Point methodologies, the core trading floor for Glaxosmithkline Pharmaceuticals Ltd today centers at a Pivot Point (PP) of ₹2494.83. Upside resistance challenges are calculated at R1: ₹2523.46, R2: ₹2540.63, and R3: ₹2569.26. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹2477.66, S2: ₹2449.03, and S3: ₹2431.86.
How does the fundamental ROE and P/E ratio look for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd is currently trading with a valuation metrics context of a Stock P/E of 43.2, against a core structural efficiency Return on Equity (ROE) standing at 45.6 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 59, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell Glaxosmithkline Pharmaceuticals Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Speculative Momentum Phase (Neutral / Hold). Glaxosmithkline Pharmaceuticals Ltd... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of C, a Relative Strength (RS) ranking of 31, and long-term trend backing from the TI65 indicator (Neutral pattern).